Pre-mRNA processing factor 19 (Prp19) activates pre-mRNA spliceosome and also mediates DNA damage response. Prp19 overexpression in cells with functional p53 leads to decreased apoptosis and increases cell survival after DNA damage. Here we showed that in hepatocellular carcinoma (HCC) cells with inactive p53 or functional p53, Prp19 was down-regulated due to the impaired stability under chemotherapeutic drug treatment. Silencing Prp19 expression enhanced apoptosis of HCC cells with or without chemotherapeutic drug treatment. Furthermore high level of Prp19 may inhibit chemotherapeutic drugs induced apoptosis in hepatocellular carcinoma cells through modulating myeloid leukemia cell differentiation 1 expression. These results indicated that targeting Prp19 may potentiate pro-apoptotic effect of chemotherapeutic agents on HCC.
References
[1]
Jemal A, Bray F (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90. doi: 10.3322/caac.20107
[2]
El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118–1127. doi: 10.1056/nejmra1001683
[3]
Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47–59. doi: 10.1038/nrm2308
[4]
Vousden KH, Prives C (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413–431. doi: 10.1016/j.cell.2009.04.037
Yin J, Zhu JM, Shen XZ (2012) New insights into pre-mRNA processing factor 19: A multi-faceted protein in humans. Biol Cell 104: 695–705. doi: 10.1111/boc.201200011
[7]
Zhang N, Kaur R, Lu X, Shen X, Li L, et al. (2005) The Pso4 mRNA splicing and DNA repair complex interacts with WRN for processing of DNA interstrand cross-links. J Biol Chem 280: 40559–40567. doi: 10.1074/jbc.m508453200
[8]
Lu X, Legerski RJ (2007) The Prp19/Pso4 core complex undergoes ubiquitylation and structural alterations in response to DNA damage. Biochem Biophys Res Commun 354: 968–974. doi: 10.1016/j.bbrc.2007.01.097
[9]
Dellago H, Khan A, Nussbacher M, Gstraunthaler A, Lammermann I, et al. (2012) ATM-dependent phosphorylation of SNEVhPrp19/hPso4 is involved in extending cellular life span and suppression of apoptosis. Aging (Albany NY) 4: 290–304.
[10]
Voglauer R, Chang MW, Dampier B, Wieser M, Baumann K, et al. (2006) SNEV overexpression extends the life span of human endothelial cells. Exp Cell Res 312: 746–759. doi: 10.1016/j.yexcr.2005.11.025
[11]
Confalonieri S, Quarto M, Goisis G, Nuciforo P, Donzelli M, et al. (2009) Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. Oncogene 28: 2959–2968. doi: 10.1038/onc.2009.156
[12]
Kuo PC, Tsao YP, Chang HW, Chen PH, Huang CW, et al. (2009) Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor. Cancer Res 69: 8877–8885. doi: 10.1158/0008-5472.can-09-2023
[13]
Sorrells S, Carbonneau S, Harrington E, Chen AT, Hast B, et al. (2012) Ccdc94 protects cells from ionizing radiation by inhibiting the expression of p53. PLoS Genet 8: e1002922. doi: 10.1371/journal.pgen.1002922
[14]
Mahajan KN, Mitchell BS (2003) Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. Proc Natl Acad Sci U S A 100: 10746–10751. doi: 10.1073/pnas.1631060100
[15]
Muller M, Strand S, Hug H, Heinemann EM, Walczak H, et al. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403–413. doi: 10.1172/jci119174
[16]
Sun L, Zhang G, Li Z, Lei T, Huang C, et al. (2008) Cellular distribution of tumour suppressor protein p53 and high-risk human papillomavirus (HPV)-18 E6 fusion protein in wild-type p53 cell lines. J Int Med Res 36: 1015–1021. doi: 10.1177/147323000803600519
[17]
Oliveri RS, Wetterslev J, Gluud C (2011) Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev: CD004787.
[18]
Gish RG, Porta C, Lazar L, Ruff P, Feld R, et al. (2007) Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25: 3069–3075. doi: 10.1200/jco.2006.08.4046
[19]
Norbury CJ, Zhivotovsky B (2004) DNA damage-induced apoptosis. Oncogene 23: 2797–2808. doi: 10.1038/sj.onc.1207532
[20]
Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T (1997) p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A 94: 9679–9683. doi: 10.1073/pnas.94.18.9679
[21]
Strasser A, Harris AW, Jacks T, Cory S (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329–339. doi: 10.1016/0092-8674(94)90201-1
[22]
Beck BD, Park SJ, Lee YJ, Roman Y, Hromas RA, et al. (2008) Human Pso4 is a metnase (SETMAR)-binding partner that regulates metnase function in DNA repair. J Biol Chem 283: 9023–9030. doi: 10.1074/jbc.m800150200
[23]
Sato M, Sakota M, Nakayama K (2010) Human PRP19 interacts with prolyl-hydroxylase PHD3 and inhibits cell death in hypoxia. Exp Cell Res 316: 2871–2882. doi: 10.1016/j.yexcr.2010.06.018
